ADVERTISEMENT

Piramal Pharma - Geared To Drive Robust Operating Leverage Across Segments: Motilal Oswal

The brokerage maintains its Buy rating on the stock with a target price of Rs 260, based on SOTP (17x EV/Ebitda for CDMO business; 13x EV/Ebitda for CHG, India consumer health business).

<div class="paragraphs"><p>Close view of holding capsules. (Photo: freepik)</p></div>
Close view of holding capsules. (Photo: freepik)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More